-
FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia
PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has… Source: Read More
-
A New Horizon: How the Schizophrenia Treatment Landscape is Evolving (2026-2036)
The Future of Schizophrenia Care The landscape for treating schizophrenia is poised for a significant transformation over the next decade. According to a recent report by DelveInsight, the market is expected to gain substantial momentum between 2026 and 2036, driven by an influx of innovative therapeutic options designed to better manage the complexities of the…